Legal and Medical Cannabis Market Sales Expected to Accelerate

NEW YORK, April 11, 2018 /PRNewswire/ --

According to a report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is projected to grow at a CAGR of 21.1% between 2017 to 2024, while reaching an estimated value of $63.5 billion by 2024. The market is going through a period of healthy growth thanks to increasing legalization and decriminalization of cannabis products across North America. The report specifies that the legalization trend is moving beyond the U.S. region. Data by Arcview Market Research explains that growth of the legal cannabis industry is expected reaccelerate this year, as sales of products for recreational use set to start in Canada, California, and Massachusetts along with medical sales in Florida. Liberty Health Sciences Inc. (OTC: LHSIF), American Cannabis Company, Inc. (OTC: AMMJ), Lexaria Bioscience Corp. (OTC: LXRP), GB Sciences, Inc. (OTC: GBLX), MPX Bioceutical Corporation (OTC: MPXEF)

According to CBC, Canada is one of only two countries, together with the Netherlands - that currently exports cannabis, allowing firms in Canada to take instant benefit of recent medical cannabis legalizations in more than 20 countries. CBC reported that the, "offerings in today's Canada medical marijuana market differ little from those used recreationally - the smokable plant and, more recently, oil extracts. More than 70 companies have licenses from the federal drug regulator, Health Canada, to cultivate, produce and sell medical marijuana, with more than half those licenses granted in 2017 or 2018."

Liberty Health Sciences Inc. (OTCQX: LHSIF) also listed on the Canadian Securities Exchange under the Ticker (CSE: LHS). Just earlier this morning the company announced breaking news that it, has recorded a 253% increase in monthly revenue since the start of 2018, and a 100% increase in its served patient count. The surge has been fueled by unprecedented growth in the number of registered medical cannabis patients and physicians in the state of Florida. So far this year, the number of registered patients in Florida has increased 46% to over 93,000 patients, and the number of recommending physicians has increased 44% as the physician community continues to witness the benefits of medical cannabis first-hand. The registered patient count in Florida is expected to continue to increase rapidly as more physicians recommend cannabis as a treatment option, and as more Florida residents become educated on the benefits of medical cannabis to treat certain qualifying conditions. The Florida Department of Health ("DOH") continues to make progress in processing the high volume of applications and issuing Medical Marijuana Use Registry identification cards, which is also helping to accelerate demand for Liberty's products throughout the state.

"Our patient-centric approach has been very well received in Florida," said George Scorsis, Director and CEO of Liberty. "Our Cannabis Education Centers, which we are continuing to roll-out across the state, provides comprehensive education, resources and compassionate one-on-one consultations geared towards educating patients on cannabis use as a safe treatment alternative to treat their symptoms. Liberty is proud to provide Florida's patients in need with convenient and timely access to high-quality, clean and safe pharmaceutical-grade medical cannabis when they need it the most."

In response to the rapidly growing patient demand, Liberty is expanding its home delivery model to bring 24-hour delivery service to patients across southern Florida. The Company has received approval from the DOH to establish a distribution center ("Hub") located in Fort Lauderdale. Supported by a fleet of eco-friendly hybrid vehicles, The Hub will provide one-day delivery service to patients in Broward, Miami-Dade and Palm Beach counties, an area with nearly 6 million people representing 29% of the state's population. Liberty is also expanding its fleet to provide one-day delivery service to patients in Alachua and Marion counties. This fast and convenient service will also be offered through Liberty's Cannabis Education Centre in The Villages and at the Company's future dispensary locations expected to open soon. In total the Company's one-day delivery service will reach 6.6 million people, or 32% of Florida's population.

"The growth in registered medical cannabis patients in Florida is far exceeding our expectations, but Liberty is fully prepared to meet the rapidly expanding demand with our production expansion currently underway at Chestnut Hill and Liberty 360 facilities and our new southern Florida distribution hub," said Scorsis. "We are committed to providing all of our patients across Florida with fast and convenient access to medical cannabis, regardless of their location in the state."

American Cannabis Company, Inc. (OTCQB: AMMJ) offers end-to-end solutions to existing and aspiring participants in the cannabis industry. Earlier this year, the company announced that it has secured a consulting contract with Cloud 9 Apothecary in the state of California. In conjunction with the consulting agreement, ACC will acquire an equity stake in Cloud 9's project that is currently non-operational and in the development stage. This project, to be built-out and completed in Desert Springs, California, will comprise a closed-loop greenhouse containing a 22,000 square foot canopy of premium cannabis cultivars. With the construction of this facility, Cloud 9 Apothecary's plans focus on wholesale cultivation and product manufacturing. Plans to shift into a fully integrated business model, complete with dispensing solutions, will be made in the near future as Cloud 9 plans to scale up operations organically.

Lexaria Bioscience Corp. (OTCQX: LXRP) has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. On March 22, 2018, the company announced it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing for "composition of matter" claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids.  This is a significant addition to Lexaria's existing manufacturing "method of use" patent rights previously granted.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods, as well as biopharmaceutical research and development. Earlier this month, the company announced it has completed the technology transfer for the manufacturing of time-released nanoparticles containing a cannabinoid-based therapeutic for neuropathic pain from the University of Seville. As announced in Q4 of 2017, GB Sciences has obtained the exclusive worldwide license to the intellectual property covering this time-released cannabinoid formulation from the University of Seville ("USE"), the Centro de Investigación Biomédica en Red de Salud Mental ("CIBERSAM") and the University of Cadiz.

MPX Bioceutical Corporation (OTCQB: MPXEF), an Ontario corporation, through its wholly owned subsidiaries in the U.S., provides substantial management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to three medicinal cannabis enterprises in Arizona operating under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates wholesale) brands. The successful Health for Life brand operates in the rapidly growing Phoenix Metropolitan Statistical Area. Recently, the company announced that the official opening of the its newest "Health for Life" medical marijuana dispensary in the Metropolitan Phoenix area, located at the junction of E. Main and Crimson in the suburb of Apache Junction. This brings the number of dispensaries under MPX management in Arizona's Sun Valley to four. The Crimson dispensary will meet the needs of patients in this comparatively underserviced southeast quadrant of the region by making available the full spectrum of MPX concentrates, an extensive variety of cannabis flower, and a broad selection of 3rd party, processed cannabis-infused edibles.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned within this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For liberty health sciences inc, financial news dissemination and PR services, FinancialBuzz.com expects to be compensated four thousand dollars by winning media. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

For further information:
[email protected]
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com